Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
Celularity Receives Nasdaq Notice Regarding Form 10-Q
August 22, 2025 17:30 ET | Source: Celularity, Inc. FLORHAM PARK, N.J.,…
